Tag: KOL & Payer Insights

Every drug development program starts with a hypothesis about the product it hopes to become. The Target Product Profile (TPP) is where that hypothesis is written down: the intended indication, the efficacy and safety thresholds, the dosing and administration, and the differentiation the asset needs... Continue reading